ArticleBritish journal of cancer2005
Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma.
Article in British journal of cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06163534 (TEMPUS PHOENIX HNSCC STUDY), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role of circulating tumor DNA and cell-free DNA biomarkers in diagnosis and prognosis of oral cancer - a systematic review.BMC oral health · 2025Pooled it
- The role of circulating tumor DNA as a prognostic biomarker in plasma of patients with oral squamous cell carcinoma.Odontology · 2026Article
- Comparison of level of circulating tumor DNA between oral squamous cell carcinoma and healthy controls: a case control study.BMC oral health · 2025Article
- Article
- Artificial Intelligence in Oral Cancer: A Comprehensive Scoping Review of Diagnostic and Prognostic Applications.Diagnostics (Basel, Switzerland) · 2025Review
- Combined detection of serum EFNA1 and MMP13 as diagnostic biomarker for gastric cancer.Scientific reports · 2024Article
- Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma.Journal of biomedical science · 2023Review
- Review
- Liquid Biopsy as a Tool for the Characterisation and Early Detection of the Field Cancerization Effect in Patients with Oral Cavity Carcinoma.Biomedicines · 2021Review
- A blood-based transcriptomic signature for noninvasive diagnosis of gastric cancer.British journal of cancer · 2021Article
- Ultrasensitive detection of tumor-specific mutations in saliva of patients with oral cavity squamous cell carcinoma.Cancer · 2021Article
- Review
- Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma.BMC cancer · 2018Review
- Liquid Biopsy in Oral Cancer.International journal of molecular sciences · 2018Review
- Liquid Biopsy in Head and Neck Cancer: Promises and Challenges.Journal of dental research · 2018Review
- Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review).International journal of oncology · 2018Review
- Genomic approaches to accelerate cancer interception.The Lancet. Oncology · 2017Review
- From Normal Skin to Squamous Cell Carcinoma: A Quest for Novel Biomarkers.Disease markers · 2016Review
- Role of Circulating Cell-Free DNA in Cancers.Molecular diagnosis & therapy · 2015Review
- Liquid biopsy: monitoring cancer-genetics in the blood.Nature reviews. Clinical oncology · 2013Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Frequent allelic imbalances (AIs) including loss of heterozygosity and microsatellite instability on a specific chromosomal region have been identified in a variety of human malignancies. The objective of our study was to assess the possibility of prognostication and monitoring of oral squamous cell carcinoma (SCC) by microsatellite blood assay. DNA from normal and tumorous tissues and serum DNA obtained at three time points (preoperatively, postoperatively, and 4 weeks postoperatively) from 64 patients with oral SCC was examined at nine microsatellite loci. In all, 38 (59%) DNA samples from tumorous tissues and 52% from serum showed AIs in at least one locus. Patterns of AIs in the serum DNA were matched to those detected in tumour DNA. Of them, AIs were frequently detected preoperatively (44%, 28 of 64), and postoperatively (20%, 13 of 64). Moreover, among 12 cases with AIs during the postoperative period, six had no evidence of an AI 4 weeks postoperatively, and they had no recurrence and were disease free. In contrast, six patients with AI-positive DNA 4 weeks postoperatively have died with distant metastasis within 44 weeks. Thus, our results suggest that the assessment of microsatellite status in the serum DNA could be a useful predictive tool to monitor disease prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.